Celltrion's Biosimilar Gets FDA Panel Nod Despite Extrapolation Concerns
Committee discussion reflects tension between desire for indication-specific efficacy data and recognition of benefits of 351(k) pathway.
Committee discussion reflects tension between desire for indication-specific efficacy data and recognition of benefits of 351(k) pathway.